Taizhou Xingcheng Chempharm Co., Ltd. established in 2005, is a technology driven manufacturer of raw materials and intermediates. Committed to providing safe and high-quality products and reliable services to the global pharmaceutical industry, we mainly engage in the research and development, production, and sales of raw materials and intermediate products. We provide customers with process research and development, product registration, and production services throughout the entire process from new product development to product launch.

At present, the company's main business is divided into two parts, including independent products and customized processing business. Regarding independent products, the company's main characteristics currently include penem and anti-tumor raw materials as well as intermediates, with a product development strategy oriented towards cardiovascular and cerebrovascular drugs. Among them, meropenem side chain, biapenem side chain, tibopenem side chain, minocycline hydrochloride, polymyxin B, and 3-hydroxyacetophenone have successfully entered several large pharmaceutical factories abroad. In addition, with the increasing trend of the transfer of foreign pharmaceutical industry to China and India in recent years, Xingcheng began to intervene in related customized research and development and entrusted processing businesses in 2009, equipped with dozens of experienced research and development personnel for support.

At present, the company's development strategy is to fully leverage its comprehensive advantages such as continuous technological innovation, efficient R&D management, and good market reputation. With independent intellectual property rights as the core, and through flexible production organization, the company continuously consolidates its pharmaceutical intermediate business. At the same time, it is committed to developing APIs that meet GMP requirements, making Xingcheng Pharmaceutical an internationally renowned company in the field of chemical medicine.